Bromocriptine: old drug, new formulation and new indication

@article{Holt2010BromocriptineOD,
  title={Bromocriptine: old drug, new formulation and new indication},
  author={R. I. G. Holt and Alina Barnett and C. J. Bailey},
  journal={Diabetes},
  year={2010},
  volume={12}
}
Bromocriptine is an ergot alkaloid dopamine D2 receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is known that hypothalamic hypodopaminergic states and disturbed circadian rhythm are associated with the development of insulin resistance, obesity and diabetes in animals and humans. When administered in the early morning at the start of the light phase, a new quick release (QR) formulation of bromocriptine appears to act… 
Bromocriptine therapy: Review of mechanism of action, safety and tolerability
TLDR
Bromocriptine represents an attractive option with high efficacy and safety profile for hyperprolactinemia‐associated conditions, acromegaly, parkinsonism, type 2 diabetes mellitus and various other diseases in a variety of dosage forms for best possible beneficial effects.
BROMOCRIPTINE - A NOVEL APPROACH FOR MANAGEMENT OF TYPE 2 DIABETES MELLITUS
TLDR
The drug is well tolerated in antidiabetic dosage with mild side effects like nausea vomiting and fatigue, and its effects to reduce adverse cardiovascular outcomes make it an attractive option for treatment of type 2 diabetes.
Bromocriptine — an old drug in a new formulation for the effective treatment of type 2 diabetes
TLDR
Bromocriptine-QR mechanism of action, unique formulation, clinical efficacy and safety, proves it to be a great alternative to current treatments for type 2 diabetes.
Effect of Bromocriptine on Insulin Resistance in Patients with PCO
TLDR
Even in the short-term consumption, bromocriptine reduced FBS and insulin levels and insulin resistance in PCO patients with pre-diabetes range.
Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus
TLDR
Recommendations include bromocriptine mesylate QR as part of dual or triple antihyperglycemic therapy especially in individuals with type 2 diabetes who are hesitant to add injectable treatment options and/or have cardiovascular disease.
The effects of hyperprolactinemia and its control on metabolic diseases
TLDR
Medical treatment with the dopamine-agonists bromocriptine and cabergoline has been shown to significantly improve gluco-insulinemic and lipid profile, and replacement treatment for concomitant hypogonadism effectively ameliorates insulin resistance and metabolic syndrome.
Efficacy of Bromocriptine for Glycemic Management in Type 2 Diabetes Mellitus
TLDR
The concomitant treatment with bromocriptine and other antiglycemic drugs was effective in glycemic control of T2DM cases.
Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas
TLDR
In hyperprolactinemic hypogonal men, proper testosterone replacement induces a significant improvement in the metabolic profile, even though the amelioration in the lipid profile might reflect the direct action of CAB.
Bromocriptine for the Treatment of Peripartum Cardiomyopathy.
TLDR
Bromocriptine, a clinically-approved drug to block prolactin release, was initially tested in a PPCM mouse model and successfully used in humans as a bench-tobedside approach, and a randomised trial that further strengthens the role of this novel and disease-specific medical treatment in addition to standard heart failure therapy in clinical practice.
Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus
TLDR
Bromocriptine is a novel therapy for type 2 diabetes mellitus patients, as its mechanism of action is unique in T2DM patients with minimal adverse effects, and the safe use of bromOCriptine in obese T1DM patients makes it a more attractive option as it causes weight loss.
...
...

References

SHOWING 1-10 OF 58 REFERENCES
Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes
TLDR
Although the mechanism of action is not fully understood, bromocriptine-QR's action points to a central target in the brain (hypothalamus) which may explain the observed peripheral improvements in metabolic parameters.
Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes.
TLDR
Once daily Ergoset treatment improves glycaemic control and serum lipid profile and is well-tolerated in obese Type 2 diabetics.
Interaction of bromocriptine and cyclosporine in insulin dependent diabetes mellitus: results from the Canadian open study.
Bromocriptine: a novel approach to the treatment of type 2 diabetes.
TLDR
Bromocriptine improves glycemic control and glucose tolerance in obese type 2 diabetic patients and is associated with enhanced maximally stimulated insulin-mediated glucose disposal.
Does Bromocriptine Improve Glycemic Control of Obese Type-2 Diabetics?
TLDR
The data further support the contention that bromocriptine improves glycemic control in obese type-2 diabetic patients, although the mechanism of action remains to be determined.
Effect of bromocriptine on maturity onset diabetes.
TLDR
It is concluded that bromocriptine lowers the blood glucose and improves glucose tolerance in maturity onset diabetics, which may be the result of the lowered prolactin which occurred without a concomitant rise in growth hormone.
Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
TLDR
The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of bromocriptine-QR, a D2 dopamine receptor agonist, as a treatment for type 2 diabetes.
Intracerebroventricular Administration of Bromocriptine Ameliorates the Insulin-Resistant/Glucose-Intolerant State in Hamsters
TLDR
Both treatments significantly improved insulin-mediated suppression of hepatic glucose production during a hyperinsulinemic-euglycemic clamp and demonstrates for the first time that the CNS is a critical target of bromocriptine’s metabolic effects.
Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women.
TLDR
Results imply that short-term bromocriptine treatment ameliorates various components of the metabolic syndrome while it shifts energy balance away from lipogenesis in obese humans.
Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine
TLDR
It is concluded that erythromycin can markedly increase the systemic bioavailability of bromocriptine, which can lead to increased therapeutic or adverse effects, whereas the effects of caffeine require further study.
...
...